Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6392.5000 48.50 (0.76%)
NSE Jan 02, 2026 15:31 PM
Volume: 108.5K
 

6392.50
0.76%
Axis Direct
While Q3 EBITDA was inline with estimate, PAT of Rs 2.68bn was 10% below our estimate due to higher taxes. Revenue growth was muted at 13% YoY (9M was 14% YoY, 10% in cc terms). Divi'sguided for 10- 15% cc revenue growth for FY17/18 vs.15% earlier, given delay in adding capacities (Vizagand Kakina..
Number of FII/FPI investors decreased from 990 to 897 in Sep 2025 qtr
More from Divi's Laboratories Ltd.
Recommended